AKARI THERAPEUTICS PLC ADS
AKARI THERAPEUTICS PLC ADS
- USD (-)
- 15 min delayed data - NASDAQ Stocks
Open: -
Change: -
Volume: -
Low: -
High: -
High / Low range: -
Type: Stocks
Ticker: AKTX
ISIN:

URGENT: Monteverde & Associates PC Invites Akari Therapeutics, Plc. Shareholders with Significant Losses To Contact The Firm Immediately - AKTX

  • 122
URGENT: Monteverde & Associates PC Invites Akari Therapeutics, Plc. Shareholders with Significant Losses To Contact The Firm Immediately - AKTX

PR Newswire

NEW YORK, June 1, 2017 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a boutique securities firm headquartered at the Empire State Building in New York City announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York against Akari Therapeutics, Plc. (NasdaqCM: AKTX)("Akari Therapeutics" or the "Company") on behalf of purchasers of the Company's securities between March 30, 2017 and May 11, 2017, inclusive (the "Class Period").

Monteverde & Associates PC Logo

The lawsuit is based on whether Akari Therapeutics and its executives violated federal securities law by misleading investors by making false and/or misleading statements regarding the Company's business, operational and compliance policies. Specifically, Chief Executive Officer Dr. Gur Roshwalb and possibly other executives, were involved in publishing false information about the Company, including false information regarding the Phase 2 PNH trial of Coversin.

On May 11, 2017, Akari Therapeutics announced that Dr. Roshwalb has been placed on administrative leave while the Board of Directors reviews whether Dr. Roshwalb and other executives were involved in a materially inaccurate research report that was released and then withdrawn on April 26, 2017 by Edison Investment Research Ltd. When the information was revealed to the public, the value of Akari Therapeutics stock dropped, causing losses to its shareholders.

Mr. Monteverde would like to personally discuss with you how to potentially recover your monetary losses, if incurred during the Class Period.

If you wish to serve as lead plaintiff, you must move the Court no later than July 11, 2017.  Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

Click here for more information: http://monteverdelaw.com/securities/It is free and there is no cost or obligation to you.

Monteverde & Associates PC is a boutique class action securities and consumer litigation law firm committed that has recovered millions of dollars and is committed to protecting shareholders and consumers from corporate wrongdoing.  Monteverde & Associates PC lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions, whereby they protect investors by recovering money and remedying corporate misconduct.

Contact:
Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave, Suite 4405
New York, NY 10118
United States of America
[email protected] 
Tel: (212) 971-1341
Attorney Advertising. (C) 2017 Monteverde & Associates PC.  Prior results do not guarantee a similar outcome with respect to any future matter.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/urgent-monteverde--associates-pc-invites-akari-therapeutics-plc-shareholders-with-significant-losses-to-contact-the-firm-immediately--aktx-300467466.html

SOURCE Monteverde & Associates PC

PR Newswire
PR Newswire

PR Newswire's news distribution, targeting, monitoring and marketing solutions help you connect and engage with target audiences across the globe.